Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002264817 | SCV002546402 | benign | Hereditary thrombocytopenia and hematologic cancer predisposition syndrome | 2022-01-22 | reviewed by expert panel | curation | Intronic variant with a MAF of 0.06181 (6.2%, 538/8704 alleles) in the African/African-American subpopulation of the gnomAD v2.1.1 cohort (≥ 0.0015 (0.15%)) (BA1). In addition, this variant is reported in 44 homozygotes in gnomAD v2.1.1 (BP2). Splice AI predicts no impact on splicing ≤ 0.20 (score: 0.00-0.06) (BP4). Intronic variants which SpliceAI ≤ 0.20 AND evolutionary conservation prediction algorithms predict the site as not conserved (phyloP100 way (GRCh38/hg38) ≤2.0). In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BA1, BP2, BP4 and BP7. |
Gene |
RCV001537390 | SCV001754267 | benign | not provided | 2019-04-29 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001537390 | SCV005310056 | benign | not provided | criteria provided, single submitter | not provided |